Validation by immunoblot analyses with recombinant full-length BP180 or NC16A showed that nine of the 23 ELISA-positive Alzheimer’s disease patients (39%) and one of four (25%) controls reacted with the proteins (Figure 1B). This evidence concerns the gene COL17A1 and Alzheimer disease.